Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-11-03
2010-10-05
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C536S024310, C514S04400A
Reexamination Certificate
active
07807818
ABSTRACT:
The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.
REFERENCES:
patent: 5654004 (1997-08-01), Okayama et al.
patent: 5783566 (1998-07-01), Mislick
patent: 5856462 (1999-01-01), Agrawal
patent: 5929226 (1999-07-01), Padmapriya et al.
patent: 6020464 (2000-02-01), Okazaki et al.
patent: 6096722 (2000-08-01), Bennett et al.
patent: 6159697 (2000-12-01), Monia et al.
patent: 6200602 (2001-03-01), Watts et al.
patent: 6251628 (2001-06-01), Nakao et al.
patent: 6455689 (2002-09-01), Schlingensiepen et al.
patent: 6479465 (2002-11-01), Strober et al.
patent: 6605443 (2003-08-01), Nakao et al.
patent: 6747014 (2004-06-01), Teng et al.
patent: 6794367 (2004-09-01), Tanida et al.
patent: 6884787 (2005-04-01), Monia et al.
patent: 6943241 (2005-09-01), Isogai et al.
patent: 7700757 (2010-04-01), Monteleone
patent: 2002/0034736 (2002-03-01), Falb et al.
patent: 2002/0061569 (2002-05-01), Haselbeck et al.
patent: 2002/0147140 (2002-10-01), Rosen et al.
patent: 2002/0177568 (2002-11-01), Stinchcomb et al.
patent: 2004/0209805 (2004-10-01), Phillips et al.
patent: 2004/0265833 (2004-12-01), Lofton-Day et al.
patent: 2005/0119203 (2005-06-01), Steinbrecher et al.
patent: 2006/0034800 (2006-02-01), Sanna et al.
patent: 2007/0042985 (2007-02-01), Monteleone
patent: 2007/0167385 (2007-07-01), Monteleone
patent: 2008/0214483 (2008-09-01), Schlingensiepen et al.
patent: 874046 (1998-10-01), None
patent: 1308459 (2003-05-01), None
patent: WO-97/30065 (1997-08-01), None
patent: WO-98/53068 (1998-11-01), None
patent: WO-99/50296 (1999-10-01), None
patent: WO-99/60012 (1999-11-01), None
patent: WO-00/06206 (2000-02-01), None
patent: WO-01/55367 (2001-08-01), None
patent: WO-01/57182 (2001-08-01), None
patent: WO-01/94629 (2001-12-01), None
patent: WO-02/00927 (2002-01-01), None
patent: WO-02/12440 (2002-02-01), None
patent: WO-02/068579 (2002-09-01), None
patent: WO-02/077183 (2002-10-01), None
patent: WO-02/085285 (2002-10-01), None
patent: WO-03/037368 (2003-05-01), None
patent: WO-2004/041170 (2004-05-01), None
patent: WO-2004/053099 (2004-06-01), None
patent: WO-2004/083389 (2004-09-01), None
patent: WO-2004/087920 (2004-10-01), None
patent: WO-2005/012875 (2005-02-01), None
patent: WO-2005/014011 (2005-02-01), None
patent: WO-2005/049642 (2005-06-01), None
patent: WO-2005/077403 (2005-08-01), None
patent: WO-2005/098041 (2005-10-01), None
patent: WO-2007/022642 (2007-03-01), None
patent: WO-2007/120847 (2007-10-01), None
patent: WO-2008/014400 (2008-01-01), None
Agrawal, S., et al., “Antisense Therapeutics: Is it as Simple as Complementary Base Recognition?”, Molecular Medicine Today, Feb. 2000 (vol. 6), pp. 72-81.
Arsura, M., et al., TGFβ1 Inhibits NF-κB/Rel Activity Inducing Apoptosis of B Cells: Transcriptional Activation of IκBα, Immunity, vol. 5, 31-40, Jul. 1996.
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,” Gastroenterology, 1999: 116: 557-565.
Boirivant, M., et al., “Oral Administration of Recombinant Cholera Toxin Subunit B Inhibits IL-12-Mediated Murine Experimental (Trinitrobenzene Sulfonic Acid) Colitis,” The Journal of Immunology, 2001, 3522-3532.
Boirivant, M., et al., “Oxazolone Colitis: A Murine Model of T Helper Cell Type 2 Colitis Treatable with Antibodies to Interleukin 4,” The Journal of Experimental Medicine, vol. 188, No. 10, Nov. 16, 1998, 1929-1939.
Christ, M., et al., “Immune Dysregulation in TGF-β1-Deficient Mice,” The Journal of Immunology, 1994, 1936-1946.
Fiocchi, C., “TGF-β/Smad Signaling Defects in Inflammatory Bowel Disease: Mechanisms and Possible Novel Therapies for Chronic Inflammation,” The Journal of Clinical Investigation, vol. 108, No. 4, Aug. 2001, 523-526.
Gorelik, L, et al., “Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease,” Immunity, vol. 12, 171-181, Feb. 2000.
Gorelik, L., et al., “Transforming Growth Factor-β in T-Cell Biology,” Nature Reviews/Immunology, vol. 2, Jan. 2002, 46-53.
Guerlavais, T., et al., “Use of Maldi-TOF Mass Spectrometry to Monitor Solid-Phase Synthesis of Oligonucleotides,” Anal Bioanal Chem (2002) 374: 57-63.
Hahm, K. B., et al., “Loss of Transforming Growth Factor β Signalling in the Intestine Contributes to Tissue Injury in Inflammatory Bowel Disease,” Gut 2001;49: 190-198.
Han, Seung H., et al., “Transforming Growth Factor-Beta 1 (TGF-β1) Promotes IL-2 mRNA Expression Through the Up-regulation of NF-κB, AP-1 and NF-AT in EL4 Cells,” The Journal of Pharmacology and Experimental Therapeutics, vol. 287, No. 3, 1998, 1105-1112.
Hayashi, H., et al., “The MAD-related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling,” Cell, vol. 89, 1165-1173, Jun. 27, 1997.
Heldin, Carl Henrik, et al., “TGF-β Signalling from Cell Membrane to Nucleus Through SMAD Proteins,” Nature, vol. 390, Dec. 4, 1997, 465-471.
Krieg et al. “Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides” Biochimica et Biophysica ActA Gene Structure and Expression, Elsevier, Amsterdam, NL, vol. 1489, No. 1, Dec. 10, 1999, pp. 107-116.
Lawrance, Ian Craig, et al., “Inflammation Location, But Not Type, Determines the Increase in TGF-β1 and IGF-1 Expression and Collagen Deposition in IBD Intestine,” Inflammatory Bowel Diseases, vol. 7, No. 1, Feb. 2001, 16-26.
Lawrance, Ian C., et al., “A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antisense Nf-κB,” Gastroenterology 2003:125:1750-1761.
Lesiak, Krystyna, et al., “2′,5′—Oligoadenylate: Antisense Chimeras—Synthesis and Properties,” Bioconjugate Chem. 1993, 4, 467-472.
Ludviksson, B.R., et al., “TGF-β Production Regulates the Development of the 2,4,6-Trinitrophenol-Conjugated Keyhold Limpet Hemocyanin-lnduced Colonic Inflammation in IL-2-Deficient Mice,” The Journal of Immunology, 1997, 3622-3628.
Calastretti A. and Nicolin A., Biotecnologie Farmacolpgiche, 1998, Cap. 8: 125-131.
Maier, Martin A., et al., “Synthesis of Chimeric Oligonucleotides Containing Phosphodiester, Phosphorothioate, and Phosphoramidate Linkages,” Organic Letters 2000, vol. 2, No. 13, p. 1819-1822.
Monteleone, G., et al., “Blocking Smad7 Restores TGF-β1 Signaling in Chronic Inflammatory Bowel Disease,” The Journal of Clinical Investigation, Aug. 2001, vol. 108, No. 4, p. 601-609.
Nakao et al. “Identification of Smad7, a TGF-β inducible antagonist of TGF-β signaling” Nature (London) (1997) 389(6651), pp. 631-635.
Neurath, M.F., et al., “Experimental Granulomatous Colitis in Mice is Abrogated by Induction of TGF-β-Medicated Oral Tolerance,” J. Exp. Med., vol. 183, Jun. 1996, p. 2605-2616.
Neurath, M., et al., “TNBS-Colitis,” Intern. Rev. Immunol., vol. 19, p. 51-62.
Podolsky, D.K., “Inflammatory Bowel Disease,” N. Engl. J. Med., vol. 347, No. 6, Aug. 8, 2002, p. 417-429.
Powrie, F., et al., “A Critical Role for Transforming Growth Factor-β but not Interleukin 4 in the Supression of T Helper Type 1-Mediated Colitis by CD45RBlowCD4+ T Cells,” J. Exp. Med., vol. 183, Jun. 1996, p. 2669-2674.
Ragas, J.A., “A Comparative Study on Methods of Optimal Sample Preparation for the Analysis of Oligonucleotides by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry,” Analyst, 2000, 125, p. 575-581.
Read, S., et al., “Induction of Inflammatory Bo
Chong Kimberly
Giuliani International Limited
Goodwin & Procter LLP
LandOfFree
Antisense oligonucleotides (ODN) against Smad7 and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides (ODN) against Smad7 and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides (ODN) against Smad7 and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4241923